The Mayo Clinic Cancer Center Pharmacy Shared Resource provides comprehensive pharmacy services in support of approximately 200 active cancer clinical trials across the 3 campuses of Mayo Rochester, Mayo Jacksonville, and Mayo Sccttsdale. The Pharmacy Shared Resource provides procurement, storage, and accountability of investigational agents. In addition, admixture of cytotoxic chemotherapy, growth factors, immunomodulatory agents, antiemetics, and supportive care medication is provided. The services of the Pharmacy Shared Resource are essential for protocol development, protocol initiation, and patient treatment on clinical trials throughout the Mayo Clinic Cancer Center. Special expertise with both investigational and commercially available cancer therapeutic agents resides in the Cancer Center Pharmacy Shared Resource, ensuring a uniformly high standard of safe and accurate treatment for all Mayo Clinic cancer patients. The utilization of the Pharmacy Shared Resource has increased over the past five years as noted by the number of patients treated on clinic trials. In 2002 the number of patients treated on clinical trials at the Mayo Clinic Cancer Center that utilized the Pharmacy Shared Resource was 1549, compared to 573 in 1997. This increase was due to the steady increase in patient accrual and the integration of Mayo Clinic Jacksonville and Mayo Clinic Scottsdale. The increased utilization of the Pharmacy Shared Resource is also demonstrated by an increased number of Mayo Clinic Cancer Center members utilizing the services of the Pharmacy core as well as the increased number of protocols in development. The main mission of the Pharmacy Shared Resource is to provide protocol development and review, investigational drug accountability, and chemotherapy admixture and dispensing services. The implementation of policies and procedures consistent with American Society of Health Systems Pharmacy guidelines and Joint Commission on Accreditation of Healthcare Organizations recommendations at each site ensures regulatory compliance and provides a uniform level of safe, high quality care to all Mayo Clinic Cancer Center patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-32
Application #
7253309
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
32
Fiscal Year
2006
Total Cost
$136,992
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567

Showing the most recent 10 out of 1129 publications